Hip Joint Injection

Evidence at a Glance

Intra-articular hip injection places anesthetic and/or corticosteroid into the hip joint for two purposes: to relieve pain from hip osteoarthritis and related pathology, and to diagnostically confirm the hip as the pain source before considering arthroplasty. Unlike the superficial trochanteric bursa, the hip joint is deep and cannot be reliably accessed by landmark palpation, so image guidance is effectively required and its coding drives the claim. Two payer facts dominate: guidance must be mapped to the correct code, and hyaluronic acid (viscosupplementation) is not covered for the hip - it is FDA-approved and covered for the knee only.

Domain	Summary
Medicare NCD	No national coverage determination specific to hip injection. Intra-articular corticosteroid injection is broadly covered when medically necessary.
Medicare LCD / Article	MAC joint-injection policies set diagnosis and frequency parameters. Separate hyaluronan LCDs cover the knee only and explicitly deny other joints (including hip) as investigational.
Commercial Coverage	Corticosteroid hip injection covered as medically necessary for qualifying hip pathology refractory to conservative care. Hip viscosupplementation is generally non-covered / investigational.
Evidence Level	Moderate for corticosteroid short-term relief in hip osteoarthritis and for diagnostic anesthetic injection to localize the pain source; weak/absent for hip hyaluronic acid.
Image Guidance	Effectively required (deep joint). Ultrasound is reported with 20611 (bundled); fluoroscopy with 20610 plus 77002; CT with 77012; MRI with 77021.
Prior Authorization	Corticosteroid injection usually not prior-authorized, though some plans review image-guided injections. Hyaluronic acid for the hip is typically denied regardless of authorization.
Conservative Therapy	Document activity modification, physical therapy, weight management, and analgesics/NSAIDs before injection to support medical necessity.
Diagnostic Block	Recognized use: an intra-articular anesthetic response helps confirm the hip as the pain generator, particularly in pre-arthroplasty decision-making.
Key Documentation	Hip pathology and laterality, provocative findings, imaging, guidance modality with retained image, injectate and units, and pre-/post pain scores.
Approval Considerations	Correct guidance-to-code mapping, laterality-specific diagnosis, documented conservative care, and avoidance of non-covered hip hyaluronic acid.

Procedure Overview

The hip is a deep ball-and-socket joint enclosed by a dense capsule and surrounded by thick soft tissue. An intra-articular hip injection introduces medication into the joint space to relieve pain from osteoarthritis, labral pathology, or inflammatory arthropathy, and/or to establish diagnostically whether the hip joint is the true source of a patient's pain. Because the joint cannot be reliably entered by feel, the injection is performed under fluoroscopic, ultrasound, or occasionally CT guidance, with contrast frequently used under fluoroscopy to confirm intra-articular needle position.

The diagnostic dimension is clinically important and operationally distinctive. In patients with concurrent hip and spine pathology, or before hip arthroplasty, a hip injection that abolishes pain helps confirm the joint as the pain generator and informs surgical decision-making. This dual diagnostic-therapeutic role shapes documentation: the record should state the purpose of the injection and, when diagnostic, the anesthetic response.

Relevant Anatomy (High-Level)

The relevant anatomy is the femoral head and acetabulum, the joint capsule and labrum, and the depth of the joint beneath the femoral neurovascular bundle and hip musculature. Two anatomic facts drive practice. First, the joint's depth and proximity to the femoral vessels make image guidance a safety and accuracy requirement rather than an option. Second, the joint's enclosed capsule means a correctly placed intra-articular injection is well contained, which is why confirmation of intra-articular position - by contrast under fluoroscopy or real-time ultrasound visualization - is central to both efficacy and documentation.

Clinical Indications

Symptomatic hip osteoarthritis with pain refractory to conservative care.
Inflammatory arthropathy or synovitis involving the hip joint.
Labral or chondral pathology contributing to intra-articular hip pain.
Diagnostic localization of the hip as the pain generator, particularly when hip and lumbar sources coexist or before arthroplasty.
Osteonecrosis (avascular necrosis) of the femoral head with intra-articular pain, in selected cases.

Patient Selection

Selection should confirm an intra-articular hip source and appropriate sequencing within the care plan:

Clinical findings consistent with an intra-articular source (groin pain, restricted internal rotation, positive provocative maneuvers).
Imaging consistent with hip pathology (radiographic osteoarthritis, labral or chondral findings on advanced imaging where indicated).
A documented trial of, or contraindication to, conservative management.
Clear clinical question when the injection is diagnostic (for example distinguishing hip from spine as the pain source).
Functional impairment the injection is intended to improve, with realistic expectations regarding corticosteroid durability.

Contraindications

Absolute	Relative
Overlying skin or soft-tissue infection; suspected septic joint.	Therapeutic anticoagulation or coagulopathy (individualized).
Known allergy to the planned injectate or contrast.	Poorly controlled diabetes (transient glycemic effect of corticosteroid).
Patient refusal or inability to cooperate.	Recent same-joint corticosteroid injection (cumulative risk).

Planned imminent arthroplasty (timing of intra-articular corticosteroid and infection risk considerations).

Medical Necessity

Medical necessity rests on documenting an intra-articular hip source and the rationale for injection. Payers commonly expect:

A clinical picture and imaging consistent with intra-articular hip pathology.
Laterality of the affected hip.
A documented conservative-care trial and its outcome, or a contraindication.
The purpose of the injection (therapeutic, diagnostic, or both) and, when diagnostic, the anesthetic response.
The medical necessity and modality of image guidance given the depth of the joint.
The functional deficit treated and the therapeutic or decision-making goal.

Medicare Coverage Guidance

No National Coverage Determination is specific to hip injection. Two coverage streams matter:

Corticosteroid / anesthetic injection. Covered when medically necessary under MAC joint-injection policy, with diagnosis and frequency parameters. Image guidance is separately reportable for fluoroscopy (77002), CT (77012), or MRI (77021); ultrasound guidance is reported with 20611 (bundled).
Hyaluronic acid (viscosupplementation). Medicare hyaluronan policy covers the knee only; intra-articular hyaluronic acid for the hip is explicitly denied as investigational. Do not bill hip viscosupplementation expecting coverage.
Single unit per joint. Report one unit of 20610/20611 per joint per encounter, even if aspiration and injection are both performed.
Laterality. Medicare instructs reporting the injection with RT on one line and LT on a second line for bilateral service; append modifier 50 for non-Medicare payers that require it.
Professional component. In a facility setting, the fluoroscopic-guidance professional component is reported as 77002 with modifier 26.

Commercial Payer Comparison

Payer / Program	Typical Posture on Hip Joint Injection
eviCore / Carelon / Cohere / Evolent	Corticosteroid joint injections are generally not managed by interventional-pain UM programs; some plans apply musculoskeletal management to image-guided injections. Verify delegation.
Cigna	Covered for qualifying hip pathology refractory to conservative care; viscosupplementation policies restrict coverage to the knee.
Aetna	Considers image-guided corticosteroid hip injection medically necessary for documented hip pathology; hip hyaluronic acid considered experimental.
UnitedHealthcare	Covers corticosteroid injection under medical policy; its viscosupplementation drug policy limits hyaluronic acid to the knee and does not support hip use.
Humana	Medicare Advantage aligns with CMS/MAC principles; commercial follows medical-necessity criteria with frequency edits.
Blue Cross Blue Shield plans	Plan-specific policies; corticosteroid injection covered for qualifying pathology; hip viscosupplementation generally non-covered. Verify the local licensee policy.

Documentation Requirements

Intra-articular hip pathology and laterality documented.
Provocative findings and relevant imaging.
Conservative therapy history and outcome.
Purpose of injection (therapeutic / diagnostic / both).
For diagnostic injection: anesthetic response documented.
Guidance modality and confirmation of intra-articular placement.
Retained guidance image (ultrasound image for 20611; fluoro contrast image).
Injectate name, concentration, and units.
Pre-injection numeric pain score.
Post-injection pain score and immediate percent relief.
Functional impairment and therapeutic / decision-making goal.
Signed and dated procedure note.

Imaging Requirements

Diagnostic imaging (radiographs, and MRI where indicated) supports the diagnosis of hip pathology and the exclusion of competing sources. Procedural guidance is distinct and, for the hip, effectively mandatory. Fluoroscopy with contrast confirms intra-articular position and is reported as 20610 plus 77002 (with modifier 26 for the professional component in a facility). Ultrasound provides real-time visualization without radiation and is reported with 20611, which bundles the guidance and requires a retained image. CT guidance (77012) is used selectively for difficult anatomy. When contrast is injected solely to confirm needle position, the service remains a joint injection; it becomes an arthrogram only when contrast is injected with the intent to outline the joint surface for a radiographic arthrogram.

Prior Authorization Workflow

Benefit verification. Confirm coverage for corticosteroid injection and guidance; confirm that hip hyaluronic acid is non-covered before offering it.
Authorization check. Determine whether the plan reviews image-guided injections through a musculoskeletal management program.
Conservative-care confirmation. Verify the documented trial satisfies the payer's expectation.
Diagnosis validation. Confirm a laterality-specific hip diagnosis the record supports.
Guidance decision. Select the modality and map it to the correct code (20611 for ultrasound; 20610 plus 77002/77012/77021 for fluoroscopy/CT/MRI).
Procedure and coding. Report one unit per joint with laterality; append modifier 26 to guidance in a facility; append modifier 25 only for a separate E/M.
Post-service integrity. Ensure intra-articular confirmation, guidance documentation, and pre-/post pain scores are recorded.

Common Prior Authorization & Claim Denials

Denial Reason	Root Cause / Prevention
Hip hyaluronic acid billed	Viscosupplementation is covered for the knee only. Do not bill hip HA; the drug and injection will deny as investigational.
20610 billed when ultrasound was used	Ultrasound-guided injection must be reported with 20611. Map the guidance modality to the correct code.
Guidance billed but not documented	Fluoroscopy/CT/MRI guidance reported without documentation or retained image. Document the modality and retain the confirming image.
Conservative care not documented	Injection billed without a visible conservative-care trial. Document the trial and outcome before the injection.
Unspecified laterality	Non-laterality diagnosis or missing RT/LT. Code laterality and report per Medicare or payer instruction.
Multiple units for one joint	More than one unit billed for the same joint/encounter. Report a single unit per joint regardless of aspiration plus injection.
Arthrography confusion	27093/27095 billed alongside 20610 for a therapeutic injection. Do not report hip arthrography with 20610 unless a true arthrogram is performed.
Missing intra-articular confirmation	No documentation of intra-articular placement. Record contrast or ultrasound confirmation.

Appeal Strategies

Submit the procedure note documenting hip pathology, laterality, guidance modality, intra-articular confirmation, injectate and units, and pre-/post pain scores.
For guidance denials, supply the retained image and the depth/safety rationale for guidance.
For conservative-care denials, attach the documented therapy trial and outcome.
For diagnostic injections, document the clinical question and the anesthetic response supporting the hip as the pain source.
Do not appeal hip hyaluronic acid denials on coverage grounds; the non-coverage is categorical.
Cite the applicable LCD/article or commercial policy establishing criteria were met.

Coding & Billing Overview

Applicable CPT® Codes

CPT®	Descriptor	Application
20610	Arthrocentesis, aspiration and/or injection; major joint or bursa, without ultrasound guidance	Hip injection under fluoroscopy/CT/MRI or (rarely) without guidance.
20611	Same, with ultrasound guidance, with permanent recording and reporting	Ultrasound-guided hip injection; guidance bundled (do not add 76942).
77002	Fluoroscopic guidance for needle placement (add-on)	With 20610 when fluoroscopy is used; add modifier 26 in a facility.
77012 / 77021	CT / MRI guidance for needle placement (add-on)	With 20610 when CT or MRI guidance is used.

HCPCS (Injectate)

Corticosteroid is reported with the appropriate J-code (for example J1030 methylprednisolone acetate 40 mg, or J3301 triamcinolone acetonide per 10 mg) on the same claim. Local anesthetics are frequently not separately payable. Hyaluronic acid supply codes (for example the J73xx series) apply to the knee; billing them for the hip results in investigational denial and should not be reported for hip injection.

Common ICD-10-CM Diagnosis Codes

Code	Description	Note
M16.11	Unilateral primary osteoarthritis, right hip	Right hip OA.
M16.12	Unilateral primary osteoarthritis, left hip	Left hip OA.
M16.10	Unilateral primary osteoarthritis, unspecified hip	Use only when laterality unknown.
M16.0	Bilateral primary osteoarthritis of hip	Bilateral primary OA.
M25.551 / M25.552	Pain in right / left hip	When a specific diagnosis is not established.
M87.051 / M87.052	Idiopathic aseptic necrosis, right / left femur	Femoral head osteonecrosis.
M24.151 / M24.152	Other articular cartilage disorders, right / left hip	Labral / chondral pathology (per documentation).

Modifiers, POS & ASC

Element	Guidance
Modifier RT / LT	Report laterality; Medicare uses RT and LT on separate lines for bilateral.
Modifier 50	For non-Medicare payers that require it for bilateral injection.
Modifier 26	On fluoroscopic/CT/MRI guidance for the professional component in a facility setting.
Modifier 25	For a significant, separately identifiable E/M on the same day.
Place of Service	POS 11 (office), 22 (hospital outpatient), or 24 (ASC) where guidance is performed.
ASC considerations	Image-guided hip injections are commonly performed in office or hospital outpatient / ASC procedure suites.

Clinical Documentation Checklist

Intra-articular hip pathology and laterality.
Provocative findings and imaging.
Conservative therapy trial and outcome.
Purpose of injection (therapeutic / diagnostic).
Guidance modality and intra-articular confirmation.
Retained guidance image on file.
Injectate name, concentration, units.
Pre-injection numeric pain score.
Post-injection pain score and percent relief.
Correct guidance-to-code mapping.
Laterality-specific diagnosis.
No hip hyaluronic acid billed.

Procedure Comparison

Feature	Hip Joint Injection	Trochanteric Bursa Injection	Knee Joint Injection
Target	Intra-articular hip	Peritrochanteric bursa	Intra-articular knee
Typical CPT®	20610 (+77002) / 20611	20610 / 20611	20610 / 20611
Guidance	Effectively required	Optional	Often landmark; guidance optional
Hyaluronic acid	Not covered (hip)	Not applicable	Covered (knee OA)
Diagnostic role	Common (pre-arthroplasty)	Limited	Occasional
Coverage focus	Hip pathology + guidance	GTPS + conservative care	Knee OA + conservative care

GoHealthcare Clinical Insights

Never let hip hyaluronic acid onto a claim. The single most predictable denial in hip injection is billed viscosupplementation, which is categorically non-covered for the hip. Build a hard stop that prevents hyaluronic acid supply codes from pairing with a hip diagnosis. Document intra-articular confirmation every time. Because guidance is expected, reviewers look for proof the needle was in the joint - a contrast image under fluoroscopy or a real-time ultrasound image. Capturing that confirmation protects both the injection and the guidance code. Name the purpose. When the injection is diagnostic, state the clinical question and record the anesthetic response. That single note element supports necessity when hip and spine pathology coexist and informs downstream surgical decisions.

GoHealthcare Leadership Perspective

Hip injection concentrates risk in two places: a categorical non-coverage (hip viscosupplementation) and a guidance-to-code mapping that is easy to get wrong. Both are preventable with system controls rather than case-by-case vigilance. The leadership priorities are a claim edit that blocks hyaluronic acid on hip diagnoses, a guidance-to-code mapping embedded in charge capture (including the facility professional-component modifier), and a documentation standard that requires intra-articular confirmation and, for diagnostic injections, the anesthetic response. Together these convert a deep-joint procedure with real coverage pitfalls into a dependable, audit-ready service line.

GoHealthcare Prior Authorization Insight

The authorization insight is to separate three coverage questions the moment a hip injection is contemplated: is corticosteroid injection covered (usually yes), does the plan review image guidance (sometimes), and is hyaluronic acid being considered (categorically non-covered for the hip). Conflating these is how practices end up with denied drugs and injections. Our quality-assurance approach front-loads all three: confirm corticosteroid coverage and any musculoskeletal-management review, confirm the guidance-to-code mapping, and affirmatively exclude hip viscosupplementation from the plan. This sequencing eliminates the categorical denial and the guidance denial that account for most hip-injection revenue loss.

GoHealthcare Case Study

The following case is a composite created for education. It does not depict any actual patient or organization.

Clinical Scenario

A patient with right groin pain and radiographic hip osteoarthritis, and coexisting lumbar degenerative changes, underwent a fluoroscopically guided diagnostic-therapeutic right hip injection to determine whether the hip was the dominant pain source before considering arthroplasty.

Documentation & Coding Challenges

Two claims from the practice illustrated recurring errors. In one, an ultrasound-guided hip injection was billed as 20610 plus 76942 rather than 20611. In another, a hyaluronic acid product was billed for a hip injection and denied as investigational, taking the injection code down with it. In the index case, the fluoroscopic guidance was billed without the modifier 26 professional component in the facility setting.

Payer & Prior Authorization Barriers

Corticosteroid injection required no prior authorization, so no checkpoint had validated the guidance mapping, the facility modifier, or the categorical non-coverage of hip hyaluronic acid before submission.

Resolution Strategy

The practice corrected the ultrasound claim to 20611, added modifier 26 to the facility fluoroscopy claim, and ceased billing hip hyaluronic acid. It documented the diagnostic anesthetic response in the index case, supporting the hip as the pain generator. Prospectively, it added a hyaluronic-acid hard stop on hip diagnoses and a guidance-to-code mapping to charge capture.

Outcome & Lessons Learned

The corrected claims were paid and the diagnostic injection informed a confident surgical decision. The lesson: hip-injection revenue integrity depends on three system controls - guidance mapping, the facility professional-component modifier, and a categorical block on hip viscosupplementation - none prompted by a prior-authorization requirement.

GoHealthcare Best Practices

Block hyaluronic acid supply codes from pairing with hip diagnoses at the claim-edit level.
Map guidance to code: ultrasound to 20611; fluoroscopy/CT/MRI to 20610 plus 77002/77012/77021; add modifier 26 in facilities.
Require documentation of intra-articular confirmation on every hip injection.
Require laterality-specific diagnosis coding and one unit per joint per encounter.
Document conservative care before injection and, when diagnostic, the anesthetic response.
Track cumulative same-joint corticosteroid injections and injection-to-arthroplasty timing.

Common Mistakes

Billing hyaluronic acid for the hip, which is categorically non-covered.
Reporting 20610 plus 76942 for an ultrasound-guided injection instead of 20611.
Omitting modifier 26 on guidance in a facility setting.
Billing hip arthrography (27093/27095) with a therapeutic 20610 injection.
Reporting multiple units of 20610 for one joint per encounter.
Using a generic hip-pain code when a specific diagnosis is documented.
Failing to document intra-articular confirmation.
Omitting the conservative-care trial or the diagnostic anesthetic response.

Pearls and Pitfalls

Pearls	Pitfalls
Confirm and document intra-articular placement every time.	Billing guidance with no confirming image.
Map guidance to code before charge capture.	Adding 76942 to an ultrasound-guided injection.
Exclude hip hyaluronic acid categorically.	Billing hip viscosupplementation and losing the injection too.
Add modifier 26 to guidance in facilities.	Reporting the global guidance code in a facility setting.
Record the diagnostic question and anesthetic response.	Treating every hip injection as purely therapeutic.

Frequently Asked Questions

What CPT code is used for an intra-articular hip injection?

20610 (without ultrasound) or 20611 (with ultrasound guidance). The hip is a major joint. Under fluoroscopy, report 20610 with 77002.

Is image guidance required for hip injection?

Effectively yes. The hip is deep and near the femoral vessels, so guidance is needed for accurate and safe intra-articular placement. Document the modality and intra-articular confirmation.

How do I code ultrasound-guided hip injection?

Report 20611, which bundles the ultrasound guidance. Do not report 20610 plus 76942.

How do I code fluoroscopic guidance?

Report 20610 with 77002. In a facility setting, append modifier 26 to 77002 for the professional component.

Is hyaluronic acid covered for the hip?

No. Hyaluronic acid is FDA-approved and covered for the knee only. Medicare and commercial policies deny hip viscosupplementation as investigational.

What happens if I bill hip hyaluronic acid anyway?

The drug denies as investigational, and the associated injection code typically denies with it. Do not bill hip HA expecting coverage.

Can hip injection be diagnostic?

Yes. An intra-articular anesthetic response helps confirm the hip as the pain source, which is valuable when hip and spine pathology coexist or before arthroplasty.

What ICD-10 codes are used?

Laterality-specific hip osteoarthritis codes (M16.11 right, M16.12 left, M16.0 bilateral), hip pain (M25.551/552), osteonecrosis (M87.05-), or cartilage disorders (M24.15-), as documented.

How many units can I bill per joint?

One unit of 20610/20611 per joint per encounter, even if aspiration and injection are both performed.

How is bilateral injection reported?

Medicare uses RT on one line and LT on a second line; non-Medicare payers may require modifier 50. Follow the payer's instruction.

Does hip injection require prior authorization?

Corticosteroid injection usually does not, though some plans review image-guided injections through musculoskeletal management. Verify the plan.

Is conservative care required first?

Frequently. Document a conservative-care trial and outcome, or a contraindication, before injection.

When is contrast use an arthrogram versus a joint injection?

Contrast used only to confirm needle position keeps the service a joint injection. It becomes an arthrogram only when contrast is injected to outline the joint surface for a radiographic arthrogram.

Should I report 27093 or 27095 for a therapeutic hip injection?

No. Do not report hip arthrography codes with a therapeutic 20610 injection unless a true arthrogram is performed.

Can I bill an E/M on the same day?

Only for a significant, separately identifiable evaluation beyond the injection decision, with modifier 25. Avoid over-applying modifier 25 to planned injection visits.

How often can a hip be injected with corticosteroid?

Repeated same-joint corticosteroid injections are limited by payer policy and clinical judgment; document justification and response.

Does timing relative to hip replacement matter?

Yes. Intra-articular corticosteroid close to arthroplasty raises infection-risk and timing considerations; document the assessment.

What imaging supports the diagnosis?

Radiographs establish osteoarthritis; MRI may characterize labral, chondral, or osteonecrotic pathology when indicated.

What is the most common hip-injection denial?

Billed hip hyaluronic acid (categorical non-coverage) and incorrect guidance coding are the leading denials.

What single control most reduces hip-injection denials?

A claim edit blocking hip hyaluronic acid, paired with a guidance-to-code mapping in charge capture.

Is CT guidance ever used?

Yes, selectively for difficult anatomy; report 20610 with 77012.

Do I document laterality even with RT/LT modifiers?

Yes. Clear documentation of the injected side and a laterality-specific diagnosis support the claim regardless of modifiers.

Key Takeaways

Hip injection is a major-joint injection requiring image guidance; map guidance to code (20611 ultrasound; 20610 plus 77002/77012/77021 for fluoroscopy/CT/MRI).
Hyaluronic acid is not covered for the hip - it is a knee-only therapy; never bill hip viscosupplementation.
Document intra-articular confirmation and, for diagnostic injections, the anesthetic response.
Use laterality-specific hip diagnosis codes; report one unit per joint per encounter.
Append modifier 26 to guidance in a facility setting.
Do not report hip arthrography (27093/27095) with a therapeutic 20610 injection.
Document conservative care before injection.

Future Outlook

Ultrasound guidance for hip injection will continue to expand as point-of-care musculoskeletal ultrasound matures, offering radiation-free real-time confirmation and reinforcing the importance of image retention for 20611. The evidence base for hip corticosteroid injection and for diagnostic intra-articular anesthetic injection in pre-arthroplasty decision-making is likely to strengthen its established roles, while hip viscosupplementation remains investigational absent FDA approval and supportive trials. Practices that enforce guidance-to-code mapping and a categorical hip-HA block now will remain compliant as payer edits tighten.

References

American Medical Association. CPT® 2026 Professional Edition (20610, 20611, 77002, 77012, 77021) and CPT® Assistant guidance on hip injection under fluoroscopy. https://www.ama-assn.org/practice-management/cpt AAPC. Coding for Joint Aspiration and Injection (guidance reporting rules). https://www.aapc.com/blog/39543-coding-for-joint-aspiration-and-injection/KZA. Coding Coaches - Hip Injection (20610 with 77002-26; not 27093). https://www.kzanow.com/coding-coaches/hip-injection Centers for Medicare & Medicaid Services. Billing and Coding: Intraarticular Knee Injections of Hyaluronan (A56157) - non-knee use denied as investigational. https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=56157 Centers for Medicare & Medicaid Services. LCD - Hyaluronic Acid Injections for Knee Osteoarthritis (L39260). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=39260 AAPC. Sticking Points for Hyaluronic Acid Knee Injection Claims (HA not covered for hip/shoulder). https://www.aapc.com/blog/93351-sticking-points-for-hyaluronic-acid-knee-injection-claims/UnitedHealthcare. Sodium Hyaluronate - Commercial Medical Benefit Drug Policy. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/sodium-hyaluronate.pdf ICD-10-CM 2026, M16.- (Osteoarthritis of hip). https://www.icd10data.com/ICD10CM/Codes/M00-M99/M15-M19/M16-American Academy of Orthopaedic Surgeons (AAOS). https://www.aaos.org American College of Radiology (ACR) guidance on image-guided joint injection. https://www.acr.org

Reading Recommendations

AMA CPT® guidance on major-joint injection and imaging-guidance reporting.
Medicare hyaluronan LCDs and articles confirming knee-only coverage.
Commercial viscosupplementation drug policies for your top payers.
AAOS and ACR guidance on hip osteoarthritis and image-guided injection.

Recommended Downloads

Hip Injection Structured Procedure Note Template (with intra-articular confirmation).
Guidance-to-Code Mapping Quick-Reference (20610 / 20611 / +77002 / +77012 / +77021).
Hip Hyaluronic-Acid Hard-Stop Claim-Edit Specification.
Diagnostic Hip Injection Documentation Template (anesthetic response).

Visual Recommendations

High-level illustration of the hip joint depth and relation to the femoral neurovascular bundle.
Guidance-to-code decision tree (ultrasound / fluoroscopy / CT / MRI).
Diagnostic-versus-therapeutic hip-injection decision flow.
Coverage matrix contrasting corticosteroid (covered) and hyaluronic acid (hip non-covered).
Coding matrix: 20610 / 20611 with guidance add-ons and modifiers.
Documentation checklist infographic for point-of-care use.

Educational Disclaimer

This document is intended for educational and operational reference purposes only. It does not replace physician clinical judgment, payer policy review, legal advice, or official CMS guidance, and it is not a procedural or physician training manual. Coverage policies, coding guidance, frequency limitations, and reimbursement requirements change frequently and vary by payer, plan, and jurisdiction; all codes and coverage criteria must be independently verified against the applicable payer policy and current regulatory sources before submission. CPT® is a registered trademark of the American Medical Association. GoHealthcare Practice Solutions assumes no liability for actions taken in reliance on this educational material.

This webpage does not replace physician judgment, official payer policy, legal advice, or current coding guidance. CPT® is a registered trademark of the American Medical Association.